ACAD
Price
$19.95
Change
+$0.06 (+0.30%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
3.54B
40 days until earnings call
Intraday BUY SELL Signals
BMRN
Price
$57.18
Change
-$1.26 (-2.16%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
11.51B
32 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACAD vs BMRN

ACAD vs BMRN Comparison Chart in %
View a ticker or compare two or three
VS
ACAD vs. BMRN commentary
Oct 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a StrongBuy and BMRN is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
ACAD vs BMRN: Fundamental Ratings
ACAD
BMRN
OUTLOOK RATING
1..100
5269
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
89100
SMR RATING
1..100
2989
PRICE GROWTH RATING
1..100
8253
P/E GROWTH RATING
1..100
862
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (62) in the Biotechnology industry is in the same range as BMRN (93). This means that ACAD’s stock grew similarly to BMRN’s over the last 12 months.

ACAD's Profit vs Risk Rating (89) in the Biotechnology industry is in the same range as BMRN (100). This means that ACAD’s stock grew similarly to BMRN’s over the last 12 months.

ACAD's SMR Rating (29) in the Biotechnology industry is somewhat better than the same rating for BMRN (89). This means that ACAD’s stock grew somewhat faster than BMRN’s over the last 12 months.

BMRN's Price Growth Rating (53) in the Biotechnology industry is in the same range as ACAD (82). This means that BMRN’s stock grew similarly to ACAD’s over the last 12 months.

BMRN's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for ACAD (86). This means that BMRN’s stock grew significantly faster than ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADBMRN
RSI
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
65%
Momentum
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
68%
MACD
ODDS (%)
Bearish Trend 5 days ago
63%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
63%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 22 days ago
77%
Bullish Trend 3 days ago
60%
Declines
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 5 days ago
60%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
61%
COMPARISON
Comparison
Oct 02, 2026
Stock price -- (ACAD: $19.89 vs. BMRN: $58.44)
Brand notoriety: ACAD and BMRN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 141% vs. BMRN: 100%
Market capitalization -- ACAD: $3.54B vs. BMRN: $11.51B
ACAD [@Biotechnology] is valued at $3.54B. BMRN’s [@Biotechnology] market capitalization is $11.51B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green while BMRN’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • BMRN’s FA Score: 1 green, 4 red.
According to our system of comparison, both ACAD and BMRN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 4 TA indicator(s) are bullish while BMRN’s TA Score has 4 bullish TA indicator(s).

  • ACAD’s TA Score: 4 bullish, 6 bearish.
  • BMRN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, BMRN is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -10.32% price change this week, while BMRN (@Biotechnology) price change was -4.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.58%. For the same industry, the average monthly price growth was -14.40%, and the average quarterly price growth was -1.79%.

Reported Earning Dates

ACAD is expected to report earnings on Nov 11, 2026.

BMRN is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Biotechnology (-3.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ACAD
Daily Signal:
Gain/Loss:
BMRN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RFIX36.571.33
+3.77%
Simplify Downside Interest Rate Hedge Strategy ETF
KMCA20.660.65
+3.27%
PLUS Korea Manufacturing Core Alliance Index ETF (KMCA)
OUNZ40.110.21
+0.53%
VanEck Merk Gold ETF (OUNZ)
JABS49.490.22
+0.45%
Janus Henderson Asset-Backed Securities ETF (JABS)
AVGV84.520.16
+0.19%
Avantis All Equity Markets Value ETF (AVGV)

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with CLDX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
-1.29%
CLDX - ACAD
45%
Loosely correlated
-0.71%
RIGL - ACAD
43%
Loosely correlated
-2.45%
IDYA - ACAD
42%
Loosely correlated
-1.59%
DNLI - ACAD
42%
Loosely correlated
-0.68%
MGTX - ACAD
40%
Loosely correlated
-3.09%
More